The Role of the Hippo Pathway in Alzheimer's Disease
Our findings reveal aberrant Hippo pathway activation and increased mutations in AD. Modulating pathway components reduces Tau toxicity and lowers Tau levels, highlighting the Hippo pathway as a potential diagnostic and therapeutic target.
Authors
- Juan Botas (ORCID: https://orcid.org/0000-0001-5476-5955)
- Ismael Al‐Ramahi (ORCID: https://orcid.org/0000-0002-1275-1114)
- Olivier Lichtarge (ORCID: https://orcid.org/0000-0003-4057-7122)
- Kwanghyuk Lee (ORCID: https://orcid.org/0000-0001-7781-9696)
- María de Haro (ORCID: https://orcid.org/0000-0002-8654-2526)
- Omar El Fadel
- Morgan Catherine Stephens
Institutions
- Baylor College of Medicine (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Institute for Neurodegenerative Disorders (US)
- Neurological Research Institute (US)
- Texas Children's Hospital (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_107695
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 0.00